Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Cancer is one of the main public health problems in the world. Systemic therapies such as chemotherapy and more recently target therapies as well as immunotherapy have improved the prognosis of this large group of complex malignant diseases. However, the frequent emergence of multidrug resistance (M...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/66752 |
| Acceso en línea: | https://hdl.handle.net/10171/66752 |
| Access Level: | acceso abierto |
| Palabra clave: | Cancer Biomarker Immunotherapy Checkpoint inhibitors Drug resistance Surmounting drug resistance |
| id |
ES_beaba889f75d3eeb10522f97ecc66c02 |
|---|---|
| oai_identifier_str |
oai:dadun.unav.edu:10171/66752 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remediesPerez-Ruiz, E. (Elisabeth)|||/items/d83c356b-f521-479f-83df-13785e169cc1Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4eKopecka, J. (Joanna)|||/items/f26ff137-211a-4a95-b95b-81ceca000f68Sarmento-Ribeiro, A.B. (Ana Bela)|||/items/3f97b344-cb6d-4660-b68a-58097bedc681García-Aranda, M. (Marilina)|||/items/7034c780-0605-465c-83e3-684285edb088De-las-Rivas, J. (Javier)|||/items/b5d1fa8a-1dd5-4d29-8fd4-804b7432de5fCancerBiomarkerImmunotherapyCheckpoint inhibitorsDrug resistanceSurmounting drug resistanceCancer is one of the main public health problems in the world. Systemic therapies such as chemotherapy and more recently target therapies as well as immunotherapy have improved the prognosis of this large group of complex malignant diseases. However, the frequent emergence of multidrug resistance (MDR) mechanisms is one of the major impediments towards curative treatment of cancer. While several mechanisms of drug chemoresistance are well defined, resistance to immunotherapy is still insufficiently unclear due to the complexity of the immune response and its dependence on the host. Expression and regulation of immune checkpoint molecules (such as PD-1, CD279; PD-L1, CD274; and CTLA-4, CD152) play a key role in the response to immunotherapy. In this regard, immunotherapy based on immune checkpoints inhibitors (ICIs) is a common clinical approach for treatment of patients with poor prognosis when other first-line therapies have failed. Unfortunately, about 70 % of patients are classified as non-responders, or they progress after initial response to these ICIs. Multiple factors can be related to immunotherapy resistance: characteristics of the tumor microenvironment (TME); presence of tumor infiltrating lymphocytes (TILs), such as CD8 + T cells associated with treatment-response; presence of tumor associated macrophages (TAMs); activation of certain regulators (like PIK3γ or PAX4) found present in non-responders; a low percentage of PD-L1 expressing cells; tumor mutational burden (TMB); gain or loss of antigen-presenting molecules; genetic and epigenetic alterations correlated with resistance. This review provides an update on the current state of immunotherapy resistance presenting targets, biomarkers and remedies to overcome such resistance.ElsevierDadun. Depósito Académico Digital Universidad de Navarra20232023-07-0320202020-01-0120202020-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/66752reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/667522026-06-21T12:47:57Z |
| dc.title.none.fl_str_mv |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies |
| title |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies |
| spellingShingle |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies Perez-Ruiz, E. (Elisabeth)|||/items/d83c356b-f521-479f-83df-13785e169cc1 Cancer Biomarker Immunotherapy Checkpoint inhibitors Drug resistance Surmounting drug resistance |
| title_short |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies |
| title_full |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies |
| title_fullStr |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies |
| title_full_unstemmed |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies |
| title_sort |
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies |
| dc.creator.none.fl_str_mv |
Perez-Ruiz, E. (Elisabeth)|||/items/d83c356b-f521-479f-83df-13785e169cc1 Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e Kopecka, J. (Joanna)|||/items/f26ff137-211a-4a95-b95b-81ceca000f68 Sarmento-Ribeiro, A.B. (Ana Bela)|||/items/3f97b344-cb6d-4660-b68a-58097bedc681 García-Aranda, M. (Marilina)|||/items/7034c780-0605-465c-83e3-684285edb088 De-las-Rivas, J. (Javier)|||/items/b5d1fa8a-1dd5-4d29-8fd4-804b7432de5f |
| author |
Perez-Ruiz, E. (Elisabeth)|||/items/d83c356b-f521-479f-83df-13785e169cc1 |
| author_facet |
Perez-Ruiz, E. (Elisabeth)|||/items/d83c356b-f521-479f-83df-13785e169cc1 Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e Kopecka, J. (Joanna)|||/items/f26ff137-211a-4a95-b95b-81ceca000f68 Sarmento-Ribeiro, A.B. (Ana Bela)|||/items/3f97b344-cb6d-4660-b68a-58097bedc681 García-Aranda, M. (Marilina)|||/items/7034c780-0605-465c-83e3-684285edb088 De-las-Rivas, J. (Javier)|||/items/b5d1fa8a-1dd5-4d29-8fd4-804b7432de5f |
| author_role |
author |
| author2 |
Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e Kopecka, J. (Joanna)|||/items/f26ff137-211a-4a95-b95b-81ceca000f68 Sarmento-Ribeiro, A.B. (Ana Bela)|||/items/3f97b344-cb6d-4660-b68a-58097bedc681 García-Aranda, M. (Marilina)|||/items/7034c780-0605-465c-83e3-684285edb088 De-las-Rivas, J. (Javier)|||/items/b5d1fa8a-1dd5-4d29-8fd4-804b7432de5f |
| author2_role |
author author author author author |
| dc.contributor.none.fl_str_mv |
Dadun. Depósito Académico Digital Universidad de Navarra |
| dc.subject.none.fl_str_mv |
Cancer Biomarker Immunotherapy Checkpoint inhibitors Drug resistance Surmounting drug resistance |
| topic |
Cancer Biomarker Immunotherapy Checkpoint inhibitors Drug resistance Surmounting drug resistance |
| description |
Cancer is one of the main public health problems in the world. Systemic therapies such as chemotherapy and more recently target therapies as well as immunotherapy have improved the prognosis of this large group of complex malignant diseases. However, the frequent emergence of multidrug resistance (MDR) mechanisms is one of the major impediments towards curative treatment of cancer. While several mechanisms of drug chemoresistance are well defined, resistance to immunotherapy is still insufficiently unclear due to the complexity of the immune response and its dependence on the host. Expression and regulation of immune checkpoint molecules (such as PD-1, CD279; PD-L1, CD274; and CTLA-4, CD152) play a key role in the response to immunotherapy. In this regard, immunotherapy based on immune checkpoints inhibitors (ICIs) is a common clinical approach for treatment of patients with poor prognosis when other first-line therapies have failed. Unfortunately, about 70 % of patients are classified as non-responders, or they progress after initial response to these ICIs. Multiple factors can be related to immunotherapy resistance: characteristics of the tumor microenvironment (TME); presence of tumor infiltrating lymphocytes (TILs), such as CD8 + T cells associated with treatment-response; presence of tumor associated macrophages (TAMs); activation of certain regulators (like PIK3γ or PAX4) found present in non-responders; a low percentage of PD-L1 expressing cells; tumor mutational burden (TMB); gain or loss of antigen-presenting molecules; genetic and epigenetic alterations correlated with resistance. This review provides an update on the current state of immunotherapy resistance presenting targets, biomarkers and remedies to overcome such resistance. |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2020 2020-01-01 2020 2020-01-01 2023 2023-07-03 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10171/66752 |
| url |
https://hdl.handle.net/10171/66752 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra |
| instname_str |
Universidad de Navarra |
| reponame_str |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| collection |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869418304811040768 |
| score |
15.300724 |